Our Pipeline

The benefit-risk profile of obeticholic acid is based on extensive data from long-term clinical-trials, published real-world evidence and external-control studies, as well as eight years of post-marketing patient experience that collectively spans more than 53,000 patient years as of April 2025.

Intercept is investigating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate for the potential treatment of individuals with PBC. Bezafibrate is a pan-peroxisome proliferatoractivated receptor (pan-PPAR) agonist that is not approved in the U.S. for any indication. Intercept has completed a Phase 1 clinical study in healthy adult subjects that assessed multiple dose combinations of OCA and bezafibrate. The company has two ongoing Phase 2 studies exploring a range of therapeutic doses for the combination of OCA and bezafibrate.

INT-787 is Intercept's next-generation farnesoid X receptor (FXR) agonist. Its characteristics provide an opportunity to explore its potential in diseases that involve the gut as well as the liver, such as severe alcohol-associated hepatitis (sAH). INT-787 is currently being evaluated in a Phase 2a proof-of-concept study.